Slide 1: Q1 2025 update
Q1 2025 update April 24, 2025
Slide 2: Agenda
Agenda • Key developments & business update • Financial performance • Outlook • Q&A Anna Bertona Thijs Bakker Group CEO Group CFO Q1 2025 update | April 24, 2025
Slide 3: Disclaimer
Disclaimer • This document may contain statements relevant to Azelis Group NV (the “Company”) and/or its affiliated companies (collectively “Azelis” or the “Azelis Group”) which are not historical facts and are hereby identified as “forward-looking statements”. Such forward-looking statements includ
Slide 4: Key developments & business update
Key developments & business update Q1 2025 update | April 24, 2025
Slide 5: Leveraging our diversified footprint to benefit from shifting sentiment
Leveraging our diversified footprint to benefit from shifting sentiment Sustained momentum with 2.5% organic revenue growth achieved in Q1 ’25, marking 1 third consecutive quarter of positive organic performance Temporary margin compression as Azelis manages cost inflation and growth 2 normalisation
Slide 6: Sustained revenue growth momentum: Q1 2025 highlights
Sustained revenue growth momentum • Revenue of EUR 1.1bn, an increase of 4.5%, driven by 2.5% organic growth, and a 2.2% revenue growth contribution from acquisitions Q1 2025 highlights • Gross profit margin of 24.0%, reflecting mix effect from higher contribution from Industrial Chemicals and recen
Slide 7: Growth drivers: Organic and M&A
Growth drivers Organic M&A End markets: IC recovery, stable LS in Q1 2025 Azelis continues to execute on its M&A growth strategy through the cycle • Sustained strength in HC&IC • Good momentum in Pharma, F&F • The acquisition of Solchem strengthens the Group’s • Stable F&N with positive volume growt
Slide 8: Financial performance
Financial performance Q1 2025 update | April 24, 2025
Slide 9: Headline P&L Q1 2025
Headline P&L Q1 2025 Azelis Group highlights Q1 2025 Q1 2024 Reported change Constant currency (EUR m) Life Sciences 693.3 668.8 3.7% 3.9% Industrial Chemicals 404.6 382.3 5.8% 6.1% Group revenue 1,097.8 1,051.0 4.5% 4.7% Gross profit 263.8 260.6 1.2% 1.4% Gross profit margin 24.0% 24.8% -77 bp -80
Slide 10: Headline growth Q1 2025
Headline growth Q1 2025 F/X M&A growth Total (in millions of €) Q1 2025 Q1 2024 Organic growth translation contribution growth EMEA 495.9 460.1 -0.6% 3.9% 4.5% 7.8% Americas 383.8 371.3 0.2% 0.4% 2.8% 3.3% Asia Pacific 218.2 219.6 -0.2% 1.6% -2.1% -0.6% Group revenue 1,097.8 1,051.0 -0.3% 2.2% 2.5%
Slide 11: Regional financial update
Regional financial update EMEA Americas Asia Pacific Adjusted Adjusted Adjusted 14.3% 12.5% 12.2% 11.2% 10.1% 10.9% EBITA EBITA EBITA margin margin margin +7.8% +3.3% € 496 -0.6% € 460 € 384 € 371 € 220 € 218 Revenue Revenue Revenue (EUR m) (EUR m) (EUR m) Conversion 54,3% 49,2% Conversion Conversio
Slide 12: Working capital
Working capital Working capital Evolution of NWC* Receivables Inventory Payables EUR million NWC/ Revenue* 15.3% 13.8% 13.4% 15.9% 13.9% 14.7% 678 558 660 628 563 467 443 445 496 554 535 376 -369 -463 -434 -487 -526 -549 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2021 2022 2023 2024 2024 Mar 20
Slide 13: Outlook
Outlook Q1 2025 update | April 24, 2025
Slide 14: Near-term and Medium-term outlook
Near-term • Risk of tariffs on prices and trade flows to be mitigated by diverse, global footprint, supported by asset-light, cash-generative business model. • Azelis has a clear commercial playbook to respond to potential tariff impact, and proven pass-through model to offset price inflation. • In
Slide 15: Innovation through formulation
Innovation through formulation